Lance Wollenberg

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake et al. · Cancer Discovery · 2017 · 419 citations · Full text

Esterase Activities in the Blood, Liver and Intestine of Several Preclinical Species and Humans

Loren Berry, Lance Wollenberg, Zhiyang Zhao · Drug Metabolism Letters · 2009 · 111 citations

Medicinal Chemistry, Biosynthesis, Tissue Differences +14

Electrocatalytic Drug Metabolism by CYP2C9 Bonded to A Self-Assembled Monolayer-Modified Electrode

Mingli Yang, Jarod L. Kabulski, Lance Wollenberg et al. · Drug Metabolism and Disposition · 2009 · 49 citations · Full text

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Lohith Bachegowda, Kerry Morrone, Shannon L. Winski et al. · Cancer Research · 2016 · 45 citations · Full text

Novel Dual Inhibitor, Mixed-phenotype Acute Leukemia, Immunology +17